[1]余 辉,李 岳,郭宝娜.非酒精性脂肪性肝病的治疗研究[J].医学信息,2019,32(14):38-41.[doi:10.3969/j.issn.1006-1959.2019.14.014]
　YU Hui,LI Yue,GUO Bao-na.Treatment of Non-alcoholic Fatty Liver Disease[J].Journal of Medical Information,2019,32(14):38-41.[doi:10.3969/j.issn.1006-1959.2019.14.014]
点击复制

非酒精性脂肪性肝病的治疗研究()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
32卷
期数:
2019年14期
页码:
38-41
栏目:
综述
出版日期:
2019-07-15

文章信息/Info

Title:
Treatment of Non-alcoholic Fatty Liver Disease
文章编号:
1006-1959（2019）14-0038-04
作者:
余 辉1; 李 岳1; 郭宝娜2
1.首都医科大学第四临床医学院，北京 100176； 2.首都医科大学附属北京同仁医院消化内科，北京 100730
Author(s):
YU Hui1; LI Yue1; GUO Bao-na2
1.Fourth Clinical Medical College,Capital Medical University,Beijing 100176,China; 2.Department of Gastroenterology,Beijing Tongren Hospital,Capital Medical University,Beijing 100730,China
关键词:
非酒精性脂肪性肝病; 运动疗法; 饮食疗法; 药物疗法; 外科手术
Keywords:
Key words：Non-alcoholic fatty liver disease; Exercise therapy; Diet therapy; Drug therapy; Surgery
分类号:
R575.5
DOI:
10.3969/j.issn.1006-1959.2019.14.014
文献标志码:
A
摘要:
非酒精性脂肪性肝病（NAFLD）是一种由胰岛素抵抗、肝脏炎症、高脂血症等多种原因导致的慢性肝脏疾病。NAFLD现已成为欧美等发达国家以及我国最常见的慢性肝病之一。根据流行病学调查显示，NAFLD在我国发病率约为15%，而在欧美等发达国家发病率已超过20%。NAFLD死亡率高于普通人群，因此针对NAFLD的有效治疗十分重要。目前在临床上针对其治疗主要包括生活方式干预、药物治疗以及外科手术治疗。本文结合国内外文献对NAFLD的治疗研究进行综述。
Abstract:
Abstract：Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease caused by various factors such as insulin resistance, liver inflammation, and hyperlipidemia. NAFLD has become one of the most common chronic liver diseases in developed countries such as Europe and the United States. According to epidemiological surveys, the incidence of NAFLD in China is about 15%, and the incidence rate in developed countries such as Europe and the United States has exceeded 20%. The mortality rate of NAFLD is higher than that of the general population, so effective treatment for NAFLD is very important. Currently, clinical treatment for its main treatment includes lifestyle intervention, drug treatment and surgical treatment. This article reviews the treatment of NAFLD in combination with domestic and foreign literature.

参考文献/References:

[1]Diehl AM,Day C.Cause,Pathogenesis,and Treatment of Nonalcoholic Steatohepatitis[J].The New England Journal of Medicine,2017,377(21):2063-2072. [2]Carr RM,Oranu A,Khungar V.Nonalcoholic Fatty Liver Disease:Pathophysiology and Management[J].Gastroenterology Clinics of North America,2016,45(4):639-652. [3]Zhu JZ,Dai YN,Wang YM,et al.Prevalence of Nonalcoholic Fatty Liver Disease and Economy[J].Digestive Diseases and Sciences,2015,60(11):3194-3202. [4]Rinella ME.Nonalcoholic fatty liver disease:a systematic review[J].JAMA,2015,313(22):2263-2273. [5]Ratziu V,Goodman Z,Sanyal A.Current efforts and trends in the treatment of NASH[J].J Hepatol,2015,62(1 Suppl):S65-S75. [6]李燕,王彩花.非酒精性脂肪性肝病的饮食治疗热点[J].实用肝脏病杂志,2017,20(5):529-532. [7]European Association for the Study of the Liver(EASL),European Association for the Study of Diabetes(EASD),European Association for the Study of Obesity(EASO).EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease[J].J Hepatol,2016,64(6):1388-1402. [8]Mosca A,Nobili V,De Vito R,et al.Serum uric acid concentrations and fructose consumption are independently associated with NASH in children and adolescents[J].J Hepatol,2017,66(5):1031-1036. [9]罗伯特·C·阿特金斯著.阿特金斯医生的饮食新习惯[M].蔺智深译.北京:中国青年出版社,2004. [10]CaminhottoRde O,Fonseca FL,Castro NC,et al.Atkins diet program rapidly decreases atherogenic index of plasma in trained adapted overweight men[J].Archives of Endocrinology and Metabolism,2015,59(6):568-571. [11]Zhang HJ,He J,Pan LL,et al.Effects of Moderate and Vigorous Exercise on Nonalcoholic Fatty Liver Disease:A Randomized Clinical Trial[J].JAMA Internal Medicine,2016,176(8):1074-1082. [12]Katsagoni CN,Georgoulis M,Papatheodoridis GV,et al.Effects of lifestyle interventions on clinical characteristics of patients with non-alcoholic fatty liver disease:A meta-analysis[J].Metabolism,2017,68(12):119-132. [13]Markowicz-Piasecka M,Huttunen KM,Mateusiak L,et al.Is Metformin a Perfect Drug? Updates in Pharmacokinetics and Pharmacodynamics[J].Current Pharmaceutical Design,2017,23(17):2532-2550. [14]Tang W,Xu Q,Hong T,et al.Comparative efficacy of anti-diabetic agents on nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus:a systematic review and meta-analysis of randomized and non-randomized studies[J].Diabetes Metab Res Rev,2016,32(2):200-216. [15]Yoneda M,Hasegawa T,Sato K.Vitamin E therapy for NAFLD/NASH[J].Nutrition,2015,31(6):898-899. [16]Corey KE,Vuppalanchi R,Wilson LA,et al.NASH resolution is associated with improvements in HDL and triglyceride levels but not improvement in LDL or non-HDL-C levels[J].Alimentary Pharmacology&Therapeutics,2015,41(3):301-309. [17]Sato K,Gosho M,Yamamoto T,et al.Vitamin E has a beneficial effect on nonalcoholic fatty liver disease:a meta-analysis of randomized controlled trials[J].Nutrition,2015,31(7-8):923-930. [18]Federico A,Dallio M,Loguercio C.Silymarin/Silybin and Chronic Liver Disease:A Marriage of Many Years[J].Molecules,2017,22(2):E191. [19]de Avelar CR,Pereira EM,de Farias Costa PR,et al.Effect of silymarin on biochemical indicators in patients with liver disease:Systematic review with meta-analysis[J].World J Gastroenterol,2017,23(27):5004-5017. [20]Valachova K,Banasova M,Topolska D,et al.Influence of tiopronin,captopril and levamisole therapeutics on the oxidative degradation of hyaluronan[J].Carbohydrate Polymers,2015,134(7):516-523. [21]Li J,Qiu X,Guo W,et al.Prospective analysis of tiopronin in prevention of sorafenib and antiviral therapy inducing liver toxicity in advanced hepatitis B virus-related hepatocellular carcinoma[J].Med Oncol,2015,32(10):238. [22]Gomes MB,Negrato CA.Alpha-lipoic acid as a pleiotropic compound with potential therapeutic use in diabetes and other chronic diseases[J].Diabetology&Metabolic Syndrome,2014,6(1):80. [23]Hosseinpour-Arjmand S,Amirkhizi F,Ebrahimi-Mameghani M.The effect of alpha-lipoic acid on inflammatory markers and body composition in obese patients with non-alcoholic fatty liver disease:A randomized,double-blind,placebo-controlled trial[J].J Clin Pharm Ther,2019,44(2):258-267. [24]van den Berg EH,Wolters AAB,Dullaart RPF,et al.Prescription of statins in suspected non-alcoholic fatty liver disease and high cardiovascular risk,a population-based study[J].Liver Int,2019. [25]Takeshita Y,Takamura T,Honda M,et al.The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism:a randomised controlled trial[J].Diabetologia,2014,57(5):878-890. [26]Ratziu V,Harrison SA,Francque S,et al.Elafibranor,an Agonist of the Peroxisome Proliferator-Activated Receptor-alpha and -delta,Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening[J].Gastroenterology,2016,150(5):1147-1159.e5. [27]Fang S,Suh JM,Reilly SM,et al.Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance[J].Nature Medicine,2015,21(2):159-165. [28]Arab JP,Karpen SJ,Dawson PA,et al.Bile acids and nonalcoholic fatty liver disease:Molecular insights and therapeutic perspectives[J].Hepatology,2017,65(1):350-362. [29]Neuschwander-Tetri BA,Loomba R,Sanyal AJ,et al.Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic,non-alcoholic steatohepatitis(FLINT):a multicentre,randomised,placebo-controlled trial[J].Lancet,2015,385(9972):956-965. [30]李军祥,陈誩,王允亮.非酒精性脂肪性肝病中西医结合诊疗共识意见(2017年)[J].中国中西医结合消化杂志,2017,25(11):805-811. [31]阳航.茵陈五苓散治疗非酒精性脂肪肝的临床研究[J].中外医学研究,2015,13(5):39-40. [32]樊永红,苗冰清.大柴胡汤加味治疗非酒精性脂肪肝63例[J].内蒙古中医药,2014,33(17):9. [33]Brito JP,Montori VM,Davis AM.Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes:A Joint Statement by International Diabetes Organizations[J].JAMA,2017,317(6):635-636. [34]Sanchez-Torrijos Y,Ampuero J,Romero-Gomez M.Cardiovascular assessment in liver transplant for non-alcoholic steatohepatitis patients:What we do,what we should do[J].World Journal of Hepatology,2017,9(15):697-703. [35]Dumortier J,Giostra E,Belbouab S,et al.Non-alcoholic fatty liver disease in liver transplant recipients:another story of "seed and soil"[J].Am J Gastroenterol,2010,105(3):613-620.

相似文献/References:

[1]龙 颖,李运泽,汤中敏,等.非酒精性脂肪性肝病与血尿酸水平测定及其临床意义[J].医学信息,2018,31(07):92.[doi:10.3969/j.issn.1006-1959.2018.07.029]
　LONG Ying,LI Yun-ze,TANG Zhong-min,et al.Determination of Serum Uric Acid Level and its Clinical Significance in Non-alcoholic Fatty Liver Disease[J].Journal of Medical Information,2018,31(14):92.[doi:10.3969/j.issn.1006-1959.2018.07.029]
[2]崔姗姗,刘 英,江 霞.非酒精性脂肪性肝病与胰岛素抵抗的研究进展[J].医学信息,2022,35(10):66.[doi:10.3969/j.issn.1006-1959.2022.10.016]
　CUI Shan-shan,LIU Ying,JIANG Xia.Research Progress on Non-alcoholic Fatty Liver Disease and Insulin Resistance[J].Journal of Medical Information,2022,35(14):66.[doi:10.3969/j.issn.1006-1959.2022.10.016]
[3]冯贺强,张彩红.肠道菌群与非酒精性脂肪肝关系的研究进展[J].医学信息,2018,31(12):47.[doi:10.3969/j.issn.1006-1959.2018.12.015]
　FENG He-qiang,ZHANG Cai-hong.Research Progress on the Relationship between Intestinal Flora and Nonalcoholic Fatty Liver[J].Journal of Medical Information,2018,31(14):47.[doi:10.3969/j.issn.1006-1959.2018.12.015]
[4]郑 颖,孙华胜,毛乾国.中医防治非酒精性脂肪性肝病研究进展[J].医学信息,2018,31(15):25.[doi:10.3969/j.issn.1006-1959.2018.15.010]
　ZHENG Ying,SUN Hua-sheng,MAO Qian-guo.Progress in Prevention and Treatment of Nonalcoholic Fatty Liver Disease by TCM[J].Journal of Medical Information,2018,31(14):25.[doi:10.3969/j.issn.1006-1959.2018.15.010]
[5]易丽华.运动疗法配合护理干预对维持性血液透析患者 营养状况及生活质量的影响[J].医学信息,2018,31(16):175.[doi:10.3969/j.issn.1006-1959.2018.16.056]
　YI Li-hua.Effect of Exercise Therapy Combined with Nursing Intervention on Nutritional Status and Quality of Life in Maintenance Hemodialysis Patients[J].Journal of Medical Information,2018,31(14):175.[doi:10.3969/j.issn.1006-1959.2018.16.056]
[6]李珊珊,陈少彬,龚先琼.中药单体治疗非酒精性脂肪性肝病研究进展[J].医学信息,2018,31(21):24.[doi:10.3969/j.issn.1006-1959.2018.21.008]
　LI Shan-shan,CHEN Shao-bin,GONG Xian-qiong.Advances in Research of Traditional Chinese Medicine Monomer in the Treatment of Non-alcoholic Fatty Liver Disease[J].Journal of Medical Information,2018,31(14):24.[doi:10.3969/j.issn.1006-1959.2018.21.008]
[7]于素芳.妊娠期糖尿病的综合干预及药物治疗[J].医学信息,2019,32(01):59.[doi:10.3969/j.issn.1006-1959.2019.01.020]
　YU Su-fang.Comprehensive Intervention and Drug Therapy for Gestational Diabetes Mellitus[J].Journal of Medical Information,2019,32(14):59.[doi:10.3969/j.issn.1006-1959.2019.01.020]
[8]黄玲玉,孙 东,蒋本君,等.天津市某区域体检人群非酒精性脂肪肝调查分析[J].医学信息,2019,32(04):99.[doi:10.3969/j.issn.1006-1959.2019.04.032]
　HUANG Ling-yu,SUN Dong,JIANG Ben-jun,et al.Investigation and Analysis of Non-alcoholic Fatty Liver Disease in Medical Examination Population in A Certain Area of Tianjin[J].Journal of Medical Information,2019,32(14):99.[doi:10.3969/j.issn.1006-1959.2019.04.032]
[9]刘雪丽,丁 劲,刘 静,等.运动疗法防治不同类型颈椎病的研究[J].医学信息,2022,35(17):170.[doi:10.3969/j.issn.1006-1959.2022.17.046]
　LIU Xue-li,DING Jin,LIU Jing,et al.Study on Prevention of Different Types of Cervical Spondylosis by Exercise Therapy[J].Journal of Medical Information,2022,35(14):170.[doi:10.3969/j.issn.1006-1959.2022.17.046]
[10]王佳欣,毛乾国.慢性乙型肝炎合并非酒精性脂肪性肝病 中医辨治的研究进展[J].医学信息,2019,32(16):38.[doi:10.3969/j.issn.1006-1959.2019.16.012]
　WANG Jia-xin,MAO Qian-guo.Advances in Research on TCM Syndrome Differentiation of Chronic Hepatitis B with Nonalcoholic Fatty Liver Disease[J].Journal of Medical Information,2019,32(14):38.[doi:10.3969/j.issn.1006-1959.2019.16.012]

更新日期/Last Update: 2019-07-15